PHVS logo

PHVS Pharvaris N.V.

NASDAQ · Biotechnology · Healthcare

$31.55
-0.73 (-2.26%)

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and ac…

Market Cap: $2.21Bpharvaris.com

Price

No data yet.

Social Signal Score

59
5d
—
30d
60
2 mentions
—
60d
60
2 mentions
—
90d
57
6 mentions
—
news: 6

Analyst Ratings

14 analysts
Buyconsensus
Strong Buy 0Buy 14Hold 0Sell 0Strong Sell 0
Avg price target$59.33+88.1%
Low $44Median $61High $75
Current Consensus

Revenue

$0.00
$0.00
Mar 2018Sep 2026

Analyst Estimates

FY2025
$-2.74
$-3.02–$-2.32
9 analysts
FY2026
$-2.69
$-3.17–$-2.29
7 analysts
FY2027
$-2.62
$-3.07–$-2.04
9 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Berndt Modig
Sector
Healthcare
Industry
Biotechnology
Employees
129
Beta
-2.46
Country
CH
Piotroski score
1 / 9 (Weak)
Altman Z-score
35.87
pharvaris.com